Patent · US Active

Modified AXL peptides and their use in inhibition of AXL signaling in anti-metastatic therapy

US9822347B2 · kind B2 · utility

2Cited by

4References

3Claims

0Family size

Assignees

Inventors

Amato J. Giaccia · Stanford, US
Erinn Bruno Rankin · Waltham, US
Jennifer R. Cochran · Stanford, US
Douglas Jones · Newton, US
Mihalis Kariolis · South San Francisco, US
Katherine Fuh · Chesterfield, US
Yu Miao · Sunnyvale, US
Susan Irene Hershenson · Newbury Park, US

Key dates

Filing date	Dec 12, 2013
Grant date	Nov 21, 2017
Priority date	—
Expiry date	Dec 12, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Y207/10001
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL, MER or Tyro3 protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL, MER or Tyro3 and its ligand GAS6.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.